24 April
Treatment of cardiovascular disease during the Covid-19 pandemic
New research has shown that although those with CVD are at risk, cardiac injury can occur in those with confirmed Covid-19 and no previous cardiovascular (CV) risk. This will increase the use of and the demand for various CV treatments as patients are treated symptomatically and potentially longer-term if the myocardium effects are long-lasting.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
BCG vaccination may induce heterologous immunity and protect against Covid-19
Preliminary reports from epidemiological studies suggest that countries with universal BCG vaccination programs have been impacted less by Covid-19, leading researchers to theorise that BCG vaccination may offer some level of heterologous immunity against Covid-19.
The impact of big pharma on Covid-19
Pharmaceutical companies taking centre stage in the Covid-19 fight, such as Gilead and Eli Lilly, are seeing positive growth on the stock market and a new burst of innovation in the infectious disease landscape as the race for treatment approval for a Covid-19 therapy takes off. But what impact are pharmaceutical companies having in a time of strong clinical need?
